Cargando…
Liposomal amphotericin B—the future
Advances in medicine have led to a growing number of people with compromised or suppressed immune systems who are susceptible to invasive fungal infections. In particular, severe fungal infections are becoming increasingly common in ICUs, affecting people within and outside of traditional risk group...
Autores principales: | Hoenigl, M, Lewis, R, van de Veerdonk, F L, Verweij, P E, Cornely, O A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9693803/ https://www.ncbi.nlm.nih.gov/pubmed/36426674 http://dx.doi.org/10.1093/jac/dkac353 |
Ejemplares similares
-
Liposomal amphotericin B—the present
por: Maertens, J, et al.
Publicado: (2022) -
Liposomal amphotericin B—the past
por: Brüggemann, R J, et al.
Publicado: (2022) -
Clinical Pharmacokinetics, Pharmacodynamics, Safety and Efficacy of Liposomal Amphotericin B
por: Groll, Andreas H, et al.
Publicado: (2019) -
Preclinical Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antifungal Activity of Liposomal Amphotericin B
por: Adler-Moore, Jill, et al.
Publicado: (2019) -
Pharmacology of Liposomal Amphotericin B: An Introduction to Preclinical and Clinical Advances for Treatment of Life-threatening Invasive Fungal Infections
por: Walsh, Thomas J, et al.
Publicado: (2019)